Drug Trial Radar · NCT00313131
Study of the Management of Vaginal Discharge in West African Using Single Dose Treatments
Last checked: Nov 19, 2026Latest source record: Apr 11, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,524
Actual
Start
Jan 2004
Primary completion
Not stated
Study completion May 2005
Sponsor
- Lead sponsor
- Université de SherbrookeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian International Development Agency
- First posted
- Apr 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomised controlled trial aimed to verify whether directly observed single dose treatment (with tinidazole+fluconazole) would be as effective as the longer standard treatments (metronidazole for 7 days, plus vaginal clotrimazole for 3 days) in the syndromic management of women presenting with vaginal discharge in primary health care centers of Ghana, Togo, Guinea and Mali. It was designed as an effectiveness trial, i.e. it was done under conditions typical of routine work in these health centers
Conditions
- Bacterial Vaginosis
- Candidiasis
- Vaginitis
Interventions
tinidazole+fluconazole vs metronidazole+clotrimazoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptomatic resolution of the vaginal discharge according to the patient
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Adabraka Polyclinic
Accra, Ghana
Suntreso Polyclinc
Kumasi, Ghana
Centre de Santé Carrière
Conakry, Guinea
Centre de Santé Madina
Conakry, Guinea
Centre de Santé d'Adakpamé
Adakpamé, Togo
Clinique IST d'Agoe Nyivé
Lomé, Togo
Clinique IST d'Amoutivé
Lomé, Togo
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.